MDRNA Spray Fails to Meet Endpoint in Phase II Obesity Trial

In MDRNA’s Phase II study assessing PYY(3-36) nasal spray, results showed the treatment did not facilitate weight loss.

The 24-week, blinded, randomized, placebo-controlled, dose-ranging trial in healthy obese patients evaluated three separate doses of the drug compared with placebo and sibutramine (Meridia) with the primary endpoint being weight loss. While it was effectively delivered through nasal administration, it did not reduce a patient’s weight, the company said.

MDRNA said it believes the treatment may still be effective when combined with other drugs.